B-type natriuretic peptide pre- dicts sudden death in patients with chronic heart failure. Circulation. 2002;105:2392 7. 89. Forfia PR, Watkins SP, Rame JE, et al. Relationship between B-type natri- uretic peptides and pulmonary capillary wedge pressure in the intensive care unit. J Am Coll Cardiol. 2005;45:1667 71. 90. Maeda K, Tsutamoto T, Wada A, et al. High levels of plasma brain natri- uretic peptide and interleukin-6 after optimized treatment for heart fail- ure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol. 2000;36:1587 93. 91. Neuhold S, Huelsmann M, Strunk G, et al. Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at dif- ferent stages of the disease. J Am Coll Cardiol. 2008;52:266 72. 92. Taub PR, Daniels LB, Maisel AS. Usefulness of B-type natriuretic peptide levels in predicting hemodynamic and clinical decompensation. Heart Fail Clin. 2009;5:169 75. 93. Bettencourt P, Azevedo A, Pimenta J, et al. N-terminal-pro-brain natri- uretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation. 2004;110:2168 74. 94. Cheng V, Kazanagra R, Garcia A, et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decom- pensated heart failure: a pilot study. J Am Coll Cardiol. 2001;37:386 91. 95. Fonarow GC, Peacock WF, Horwich TB, et al. Usefulness of B-type natri- uretic peptide and cardiac troponin levels to predict in-hospital mortality from ADHERE. Am J Cardiol. 2008;101:231 7. 96. Logeart D, Thabut G, Jourdain P, et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol. 2004;43:635 41. 97. Maisel A, Hollander JE, Guss D, et al. 